72 related articles for article (PubMed ID: 21618542)
1. The use of 13C-erythromycin as an in vivo probe to evaluate CYP3A-mediated drug interactions in rats.
Sugiyama E; Kikuchi A; Inada M; Sato H
J Pharm Sci; 2011 Sep; 100(9):3995-4005. PubMed ID: 21618542
[TBL] [Abstract][Full Text] [Related]
2. 13C-erythromycin breath test as a noninvasive measure of CYP3A activity in newborn infants: a pilot study.
de Wildt SN; Berns MJ; van den Anker JN
Ther Drug Monit; 2007 Apr; 29(2):225-30. PubMed ID: 17417078
[TBL] [Abstract][Full Text] [Related]
3. Early postoperative erythromycin breath test correlates with hepatic cytochrome P4503A activity in liver transplant recipients.
Schmidt LE; Olsen AK; Stentoft K; Rasmussen A; Kirkegaard P; Dalhoff K
Clin Pharmacol Ther; 2001 Nov; 70(5):446-54. PubMed ID: 11719731
[TBL] [Abstract][Full Text] [Related]
4. Glycyrrhizin accelerates the metabolism of triptolide through induction of CYP3A in rats.
Tai T; Huang X; Su Y; Ji J; Su Y; Jiang Z; Zhang L
J Ethnopharmacol; 2014 Mar; 152(2):358-63. PubMed ID: 24486211
[TBL] [Abstract][Full Text] [Related]
5. Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization.
Chiou WL; Jeong HY; Wu TC; Ma C
Clin Pharmacol Ther; 2001 Oct; 70(4):305-10. PubMed ID: 11673745
[No Abstract] [Full Text] [Related]
6. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
Fenneteau F; Poulin P; Nekka F
J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
[TBL] [Abstract][Full Text] [Related]
7. Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer.
Calvert H; Twelves C; Ranson M; Plummer R; Fettner S; Pantze M; Ling J; Hamilton M; Lum BL; Rakhit A
Anticancer Drugs; 2014 Aug; 25(7):832-40. PubMed ID: 24637575
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous Assessment of Hepatic Transport and Metabolism Pathways with a Single Probe Using Individualized PBPK Modeling of
Franchetti Y; Nolin TD
J Pharmacol Exp Ther; 2019 Oct; 371(1):151-161. PubMed ID: 31399494
[TBL] [Abstract][Full Text] [Related]
9. Investigation of aortic CYP3A bioactivation of nitroglycerin in vivo.
Yuan R; Sumi M; Benet LZ
J Pharmacol Exp Ther; 1997 Jun; 281(3):1499-505. PubMed ID: 9190888
[TBL] [Abstract][Full Text] [Related]
10. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.
Guo H; Liu C; Li J; Zhang M; Hu M; Xu P; Liu L; Liu X
J Pharm Sci; 2013 Aug; 102(8):2819-36. PubMed ID: 23760985
[TBL] [Abstract][Full Text] [Related]
11. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
[TBL] [Abstract][Full Text] [Related]
12. Effect of CYP3A inhibition on vesnarinone metabolism in humans.
Wandel C; Lang CC; Cowart DC; Girard AF; Bramer S; Flockhart DA; Wood AJ
Clin Pharmacol Ther; 1998 May; 63(5):506-11. PubMed ID: 9630823
[TBL] [Abstract][Full Text] [Related]
13. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity.
Kurnik D; Wood AJ; Wilkinson GR
Clin Pharmacol Ther; 2006 Sep; 80(3):228-34. PubMed ID: 16952489
[TBL] [Abstract][Full Text] [Related]
14. Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin.
Elens L; Nieuweboer AJ; Clarke SJ; Charles KA; de Graan AJ; Haufroid V; van Gelder T; Mathijssen RH; van Schaik RH
Pharmacogenet Genomics; 2013 Mar; 23(3):148-55. PubMed ID: 23324807
[TBL] [Abstract][Full Text] [Related]
15. The erythromycin breath test for the prediction of drug clearance.
Rivory LP; Slaviero KA; Hoskins JM; Clarke SJ
Clin Pharmacokinet; 2001; 40(3):151-8. PubMed ID: 11327195
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine.
Stein CM; Kinirons MT; Pincus T; Wilkinson GR; Wood AJ
Clin Pharmacol Ther; 1996 Jan; 59(1):47-51. PubMed ID: 8549033
[TBL] [Abstract][Full Text] [Related]
17. Simvastatin does not affect CYP3A activity, quantified by the erythromycin breath test and oral midazolam pharmacokinetics, in healthy male subjects.
Prueksaritanont T; Vega JM; Rogers JD; Gagliano K; Greenberg HE; Gillen L; Brucker MJ; McLoughlin D; Wong PH; Waldman SA
J Clin Pharmacol; 2000 Nov; 40(11):1274-9. PubMed ID: 11075313
[TBL] [Abstract][Full Text] [Related]
18. Investigation of drug-drug interaction via mechanism-based inhibition of cytochrome P450 3A by macrolides in dexamethasone-treated female rats.
Kanazu T; Sato N; Kadono K; Touchi A; Takeda Y; Yamaguchi Y; Baba T
Biopharm Drug Dispos; 2012 May; 33(4):195-206. PubMed ID: 22447511
[TBL] [Abstract][Full Text] [Related]
19. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test.
Cheng CL; Smith DE; Carver PL; Cox SR; Watkins PB; Blake DS; Kauffman CA; Meyer KM; Amidon GL; Stetson PL
Clin Pharmacol Ther; 1997 May; 61(5):531-43. PubMed ID: 9164415
[TBL] [Abstract][Full Text] [Related]
20. Physiologically based pharmacokinetic modeling for assessing the clinical drug-drug interaction of alisporivir.
Xia B; Barve A; Heimbach T; Zhang T; Gu H; Wang L; Einolf H; Alexander N; Hanna I; Ke J; Mangold JB; He H; Sunkara G
Eur J Pharm Sci; 2014 Oct; 63():103-12. PubMed ID: 25008118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]